First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
A phase 1/2 trial of CRB-601 monoclonal antibody in advanced solid tumours, run by Corbus Pharmaceuticals Inc., now recruiting.
Overview
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. is a phase 1/2 interventional study registered as NCT06603844 by Corbus Pharmaceuticals Inc., with 156 participants planned, started 2024-12-04 and due to reach its primary completion in 2026-11-01. Interventions recorded: CRB-601 monoclonal antibody and Anti-PD-1 monoclonal antibody.
Similar pages
not linked directly; found by shared links- TrialA Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
Shares Corbus Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TreatmentCRB-701
Shares Corbus Pharmaceuticals and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.